What it is
5-Amino-1MQ is a small molecule, a lab-made chemical rather than a chain of amino acids1. It blocks an enzyme called NNMT (nicotinamide N-methyltransferase)1. NNMT moves a small chemical tag, a methyl group, onto a molecule called nicotinamide, and higher NNMT levels have been linked to obesity and type 2 diabetes4. In fat cells grown in a lab, blocking NNMT raised levels of NAD+, a helper molecule cells use to make energy, and cut down fat-making1.
What makes it distinct
It isn't a peptide. It's a small molecule, and it works by blocking an enzyme, NNMT1.
What the evidence shows
All the published research we found is in animals and cells123. In obese mice on a high-fat diet, 11 days of injections under the skin lowered body weight and fat mass, without changing how much the mice ate1. In obese mice switched to a low-fat diet, adding it led to more fat and weight loss than the diet switch alone3. In old mice with an injured leg muscle, injections improved how well the muscle grew back and how strongly it contracted2. We found no study in people, and no trial of it is registered on ClinicalTrials.gov6.
Open questions
- Whether any of the mouse results happen in people. Our sources include no study in people6.
- How it behaves in the body: how much is absorbed when swallowed, how long it lasts, and what it does to NAD+ in people. Lab tests that model the gut wall, one with an artificial membrane and one with a layer of cells, suggested it could be absorbed well by mouth, but none of this has been measured in people16.
- Safety in people. The main mouse study saw no obvious bad effects over 11 days, and our sources have no safety data in people16.
Worth knowing
In a January 2026 warning letter to an outsourcing facility, a type of compounder that registers with the FDA, the FDA said drugs made there with 5-amino-1MQ didn't qualify for the legal exemptions such facilities rely on, because it isn't on the list of bulk ingredients they may use and isn't used to make a drug in shortage5.
Sources
- Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol 2018;147:141-152 (PMID 29155147; full text PMC5826726)
- Neelakantan H, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochem Pharmacol 2019;163:481-492 (PMID 30753815)
- Dimet-Wiley A, et al. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Sci Rep 2022;12:484 (PMID 35013352)
- Kannt A, et al. A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders. Sci Rep 2018;8:3660 (PMID 29483571)
- FDA Warning Letter WL #718739 to an outsourcing facility, January 20, 2026
- ClinicalTrials.gov registry search for '5-amino-1MQ' and '5-amino-1-methylquinolinium' (API v2 queried 2026-10-27; totalCount 0 for both terms)